|
Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysis. |
|
|
Honoraria - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer |
Consulting or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis |
Travel, Accommodations, Expenses - Argos Therapeutics; Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen; Novartis; Peloton Therapeutics; Pfizer |
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer |
Research Funding - Pfizer (Inst) |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Ipsen; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; PharmaMar; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; Cerulean Pharma; Ipsen; Lilly; MSD Oncology; Novartis; Pfizer |
Speakers' Bureau - Novartis; Pfizer |
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer |
|
|
Honoraria - NCCN; UpToDate |
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech |
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst) |
Travel, Accommodations, Expenses - advisory boards/consultancy |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |